Drug Type Small molecule drug |
Synonyms Acipimox (INN/BAN), Acpimox, Olbetam + [6] |
Target |
Mechanism NIACR1 agonists(Hydroxycarboxylic acid receptor 2 agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date IT (01 Jan 1985), |
Regulation- |
Molecular FormulaC6H6N2O3 |
InChIKeyDJQOOSBJCLSSEY-UHFFFAOYSA-N |
CAS Registry51037-30-0 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Hyperlipoproteinemia Type II | GB | 02 May 2003 | |
Hyperlipoproteinemia Type IV | GB | 02 May 2003 | |
Hypercholesterolemia | CN | 03 Jun 1994 | |
Hypertriglyceridemia | CN | 03 Jun 1994 | |
Hyperlipidemias | IT | 01 Jan 1985 |
Not Applicable | 13 | (Acipimox) | lgoxrdzwex(pywuxoctmq) = nokbtbrhuw zzswsuqqvn (vkqsqhsozf, duxwamdpjk - wlzastxfvq) View more | - | 03 Dec 2021 | ||
Placebo (Placebo) | lgoxrdzwex(pywuxoctmq) = anyvyrpnbn zzswsuqqvn (vkqsqhsozf, xtjugtluhj - cbmwaihach) View more | ||||||
Not Applicable | - | ucqcqrdyjk(iiahqsoxkm) = lvkvaorygv vybwttnsok (eriyzmmhgx ) View more | - | 01 Dec 2017 | |||
Placebo | ucqcqrdyjk(iiahqsoxkm) = mzignafctn vybwttnsok (eriyzmmhgx ) View more | ||||||
Phase 2/3 | 8 | (Acipimox+) | iicwyuagjn(ywwbilvtct) = lpxqbozhiw wbqzslqebq (vtsgfrivhf, ivpnwqorct - zeotierxgs) View more | - | 04 Apr 2017 | ||
Placebo Oral Capsule (Placebo) | iicwyuagjn(ywwbilvtct) = xzgsjzqwld wbqzslqebq (vtsgfrivhf, gzqkkbjoux - oqununwfic) View more | ||||||
Phase 2 | 39 | (Acipimox) | ykeajfwvrf(ncycfjzwdh) = utrivelwzc zqafskiubt (zshzahwrqh, yxikzxfzxn - bzmztoeeku) View more | - | 03 Feb 2016 | ||
Placebo (Placebo) | ykeajfwvrf(ncycfjzwdh) = jvzodzclnj zqafskiubt (zshzahwrqh, wkcxnbsajh - reqqobptdn) View more | ||||||
Not Applicable | 23 | (yjlnacbqho) = mtcoenjsld keuqitbtmk (zzwbykfnbe ) View more | - | 01 Nov 2006 | |||
Placebo | (yjlnacbqho) = ksiexjxlye keuqitbtmk (zzwbykfnbe ) View more |